Trial
NCT05574335
Siplizumab in T1DM
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
Type 1 Diabetes Mellitus
Intervention
Siplizumab
Why stopped
Prior to termination the DESIGNATE study was an on enrollment hold due to greater than anticipated lymphodepletion. The pharmaceutical partner decided not to reopen its own T1D trial and ceased development of siplizumab in autoimmunity.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-11